ACADIA Pharmaceuticals Coverage Initiated by Analysts at Cantor Fitzgerald. (ACAD)
ACAD has been the subject of a number of other recent research reports. Analysts at Cowen initiated coverage on shares of ACADIA Pharmaceuticals in a research note to investors on Monday, January 28th. They set an outperform rating on the stock. Analysts at Piper Jaffray initiated coverage on shares of ACADIA Pharmaceuticals in a research note to investors on Thursday, January 3rd. They set a neutral rating on the stock.
Five analysts have rated the stock with a buy rating, and one has issued a hold rating to the company. The company has a consensus rating of buy and a consensus price target of $8.40.
ACADIA Pharmaceuticals traded up 1.64% on Tuesday, hitting $6.19. ACADIA Pharmaceuticals has a 52-week low of $1.29 and a 52-week high of $6.88. The stock’s 50-day moving average is currently $6.1. The company’s market cap is $350.5 million.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.